Advertise on podcast: NETWise

When cancer enters a relationship, how do you keep talking, stay close, and understand what each other needs? A diagnosis can affect communication, intimacy, and the roles partners play in each other’s lives. But staying connected doesn’t have to mean keeping everything the way it was. Sometimes it means having an uncomfortable conversation, asking for support, or finding a different way to be close. In this episode, Ken, who has been living with neuroendocrine cancer since 2016, and his wife Cindy share honest reflections on facing uncertainty together. They talk about the instinct to protect each other, balancing caregiving with self-care, and the small, everyday gestures that make them feel loved. Psychologist Dr. Joelle Kruml explores how couples can navigate changing roles, communicate their needs, and expand their understanding of intimacy. Hematologist Dr. Sigrun Einarsdottir discusses sexual intimacy during treatment, gaps in the available evidence, and why patients and clinicians need to make room for these conversations. Hosted by Jessica Thomas, NETRF’s Director of Patient Education, this episode explores: Staying connected as partners while navigating patient and caregiver rolesSharing worries instead of carrying them aloneMaking space for both partners’ needsFinding emotional and physical closeness when intimacy changesTalking with your care team about sexual activity during treatmentSeeking support from friends, support groups, and mental health professionalsWhether you’re a patient, partner, or caregiver, this conversation offers practical perspectives on communication, intimacy, and finding your way through cancer together. Learn more about neuroendocrine cancer research, education, and patient resources at NETRF.org. NETWise is produced by Deren Abram at Two24Media for the Neuroendocrine Tumor Research Foundation. NET specialists included in this episodeUse our episode infographics to get a visual picture of some of the things we have discussed. Joelle Kruml, PsyD, ABPP, Clinical Psychologist, Southeast Psychotherapy Sigrun Einarsdottir, MD, PhD, Hematologist, Sahlgrenska University Hospital A special thank you to Ken and Cindy for sharing their neuroendocrine cancer journey. Download a transcript of this episode. The post EP 57: When Cancer Enters a Relationship appeared first on NETRF.

Understanding the Evolution of Neuroendocrine Cancer In medicine, there’s an old saying: “When you hear hoofbeats, think horses, not zebras.” It’s a reminder to look for the most common explanation first. But for people living with neuroendocrine cancer… zebras matter. What happens when a slow-growing tumor begins behaving aggressively? When a diagnosis evolves over time? Or when the biology of a tumor no longer matches the original pathology report? For people living with neuroendocrine cancer, these changes can be frightening. But understanding them may also open the door to better treatment decisions, more personalized care, and new directions in research. In this episode of NETWise, we explore the evolving science of tumor heterogeneity, grade progression, and changing biology in neuroendocrine cancers — alongside the very human stories of living through those changes. Leading experts inluding Dr. Aman Chauhan (UCSF), Dr. Nancy Joseph (UCSF), Dr. Mark Lewis (Intermountain Healthcare), and Dr. Jaydira Del Rivero (National Cancer Institute) discuss the latest research and clinical insights surrounding these important questions. You’ll also hear powerful personal stories from Shari Schutz and Barbara Dunham, who share their experiences navigating changing diagnoses, evolving pathology, treatment transitions, and the importance of self-advocacy. Topics discussed include: Why the zebra became the symbol of neuroendocrine cancerTumor heterogeneity and why no two NETs are alikeGrade progression and changing tumor biologyNETs, NECs, and MiNENs explainedThe role of pathology review, re-biopsy, and advanced imagingDOTATATE PET and FDG PET scansTreatment adaptation and personalized carePatient advocacy, resilience, and living with uncertaintyAs researchers continue to learn more about how neuroendocrine cancers evolve, understanding these changes may help patients and caregivers make more informed decisions and better navigate the road ahead. Learn more about neuroendocrine cancer research, education, and patient resources at NETRF.org. #NETCancer #NeuroendocrineTumors #NETRF #NETWise #CancerPodcast #RareDisease #PatientEducation #NeuroendocrineCancer #CancerResearch #CancerAwareness NET specialists included in this episodeUse our episode infographics to get a visual picture of some of the things we have discussed. Nancy Joseph, MD, PhD Professor of Surgical Pathology, University of California, San Francisco (UCSF) Aman Chauhan, MD University of California, San Francisco Jaydira Del Rivero, MD NET Specialist, National Cancer Institute (NCI) Mark Lewis, MD Director of Gastrointestinal Oncology, Intermountain Healthcare A special thank you to Shari Schutz and Barbara Dunham for sharing their neuroendocrine cancer journey. Download a transcript of this episode. The post EP 55: Do Zebras Change Their Stripes? appeared first on NETRF.

When someone is diagnosed with cancer, one of the first questions is simple: What happens next? But for many, that question doesn’t come with a clear answer. Instead, it opens the door to something much harder to navigate—uncertainty. In this episode of NETWise, host Jessica Thomas explores what it means to live in that space of the unknown. From the shock of diagnosis to the ongoing reality of treatment decisions, scan results, and everything in between, uncertainty becomes a constant companion for many people living with neuroendocrine cancer. Through deeply personal stories and expert insight, this episode brings together the voices of patients, a caregiver, and a physician who is also a patient—each offering a different perspective on how to cope, adapt, and move forward without all the answers. You’ll hear from: Jackie Dong, diagnosed at just 23, navigating recovery and redefining his outlook on lifeDr. Mark Lewis, oncologist and patient, sharing the limits of statistics and the reality of lived experienceJennifer Rogers Anderson, who found peace by letting go of the need to knowJessica Ochoa, confronting the hardest question—how much time do I have?Gary Murfin, emphasizing the importance of self-advocacy and informed decision-makingJamie Metzl, a caregiver whose search for knowledge became deeply personalTogether, their stories reveal a powerful truth: uncertainty doesn’t just happen at diagnosis—it continues throughout the cancer journey. It shows up in treatment decisions, in waiting for scan results, in understanding the disease itself, and in imagining the future. But while uncertainty may not go away, the way we relate to it can change. This episode explores: The emotional impact of a cancer diagnosis and the shock that followsWhy statistics and percentages don’t always translate to individual experienceThe balance between seeking information and avoiding overwhelmThe reality of “scan-xiety” and living between resultsHow routines, movement, and mindset can create stabilityThe importance of self-advocacy and trusted informationWhat it means to not just survive—but thrive—within uncertaintyAt its core, this conversation is about learning how to live alongside uncertainty—not by eliminating it, but by finding ways to stay grounded, present, and connected to what matters most. Because while the future may not always be clear… the way we show up for each day still is. NET specialists included in this episodeUse our episode infographics to get a visual picture of some of the things we have discussed. Mark Lewis, MD, Director of Gastrointestinal Oncology, Intermountain Healthcare A special thank you to Jackie Dong, Jennifer Rogers Anderson, Jamie Metzl, Jessica Ochoa, Gary Murfin, Dr. Mark Lewis, for sharing her neuroendocrine cancer journey. Download a transcript of this episode. The post Episode 54: Sitting With Uncertainty appeared first on NETRF.

When someone is diagnosed with cancer, one of the first questions is simple — what exactly is it? The answer begins with better understanding pathology. In this episode of NETWise, we examine the central role pathology plays in the diagnosis and management of neuroendocrine cancers — from initial biopsy through classification, grading, and treatment decision-making. Drawing on insights from leading clinicians, pathologists, and researchers, this conversation provides a clear, structured look at how diagnostic precision is established and why it is essential. A biopsy — analyzed through pathology — is the gold standard for confirming a cancer diagnosis. By examining tumor tissue, pathologists determine not only whether cancer is present, but also define tumor type, differentiation, grade, and key biomarkers that directly inform prognosis and therapeutic strategy. In neuroendocrine neoplasms, this level of detail is particularly critical. These diseases represent a heterogeneous spectrum, where tumors that may appear similar under the microscope can behave very differently clinically. Distinguishing between well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs), as well as accurately assessing measures of tumor growth, can significantly alter treatment pathways and outcomes. This episode focuses on how those distinctions are made — and why they matter. It explores how pathology moves from a small tissue sample to a precise diagnosis, why interpretation can be complex, and why expert review is often essential, particularly in rare and high-grade disease. We also address the real-world challenges of pathology interpretation in neuroendocrine cancer, including diagnostic complexity, evolving classification systems, and the importance of second opinions and specialized care. For patients and caregivers, understanding pathology can help turn a confusing report into meaningful, actionable information. It can clarify what a diagnosis means, why specific treatments are recommended, and when it may be important to seek additional expertise. It can also help patients ask better questions — about tumor type, grade, and next steps — and better understand the reasoning behind clinical decisions. And behind every pathology report is a team of specialists looking closely and intentionally at the evidence — working to understand the biology of the disease as clearly as possible so that the next steps are as informed as possible. Because understanding pathology isn’t just about learning the science. It’s about turning confusion into clarity. It’s about knowing what questions to ask. And it’s about feeling more informed, more prepared, and more empowered in the moments that matter most. This episode is designed to help bring that clarity — to better understand and demystify pathology, and to make the information behind a diagnosis more accessible, so patients and families can move forward with greater confidence. NET specialists included in this episodeUse our episode infographics to get a visual picture of some of the things we have discussed. Neil Renwick, MD, PhD, FRCPC Assistant Professor, Department of Pathology & Molecular Medicine, Queen’s University (SEAMO New Clinician-Scientist Program) Nancy Joseph, MD, PhD Professor of Surgical Pathology, University of California, San Francisco (UCSF) Aman Chauhan, MD University of California, San Francisco Jerome Cros, MD, PhD, Beaujon Hospital, Paris A special thank you to Paige Corrente for sharing her neuroendocrine cancer journey. Download a transcript of this episode. The post Episode 53: Understanding Pathology appeared first on NETRF.

Over the past several decades, neuroendocrine cancer diagnoses have increased significantly—raising an important question: Are these cancers becoming more common, or are we simply getting better at finding them? In this episode of NETWise, leading clinicians, researchers, and a patient share what the data—and real-world experience—reveal about this trend. Drawing on insights from global experts and patient perspectives, this conversation explores how advances in imaging, pathology, and research are reshaping what we know about neuroendocrine cancer—and why earlier recognition is changing the landscape of care. In this episode, you’ll hear about: Why diagnoses have risen dramatically in recent decades—and why improved detection explains much of the increaseHow modern imaging, screening, and updated classification systems are helping doctors identify tumors earlier and more accuratelyThe environmental, biological, and social factors researchers are still working to understandWhy many tumors are now discovered incidentally, before symptoms appearHow earlier detection creates both new opportunities—and new questions—about screening and treatment decisionsA patient’s personal story of diagnosis and how awareness can lead to earlier answers and better outcomesAs understanding grows, so does the ability to diagnose neuroendocrine cancer with greater precision—and to treat it more effectively. This episode brings clarity to what’s behind the rising numbers and what that progress means for patients and families today. Whether you’re a patient, caregiver, clinician, or advocate, this episode offers clear, accessible insights into the breakthroughs driving research forward.   Please like, share, and subscribe. Your engagement helps us reach more patients and caregivers seeking reliable neuroendocrine cancer information—and supports NETRF’s mission to expand research, awareness, and hope across the NET community. NET specialists included in this episodeUse our episode infographics to get a visual picture of some of the things we have discussed. Ulrich-Frank Pape, MD Gastroenterologist, Asklepios Klinik St. Georg, Hamburg, Germany Arvind Dasari, MD Gastrointestinal Medical Oncologist, MD Anderson Cancer Center Neil Renwick, MD, PhD, FRCPC Assistant Professor, Department of Pathology & Molecular Medicine, Queen’s University (SEAMO New Clinician-Scientist Program) Nancy Joseph, MD, PhD Professor of Surgical Pathology, University of California, San Francisco (UCSF) A special thank you to Jessica Ochoa for sharing her neuroendocrine cancer journey. Download a transcript of this episode. The post Episode 52: Why Is Neuroendocrine Cancer on the Rise? appeared first on NETRF.

As we turn the page on a new year, the neuroendocrine cancer community isn’t just reflecting on progress—we’re looking ahead. This episode of NETWise explores where the field is going next, and what that future means for patients, caregivers, and clinicians alike. Recorded in connection with the 2025 NETRF Neuroendocrine Cancer Research Symposium, this conversation brings together researchers, physicians, patient advocates, and NETRF leaders to examine the momentum shaping the years ahead. In this episode, you’ll hear about: How emerging therapies—from PRRT advances to immune-based and cell therapies—are changing careWhy precision medicine, surface targeting, and biomarkers are defining the next era of researchNETRF’s research roadmap, focused on early detection, improved treatments, and precision medicine.The growing role of patient education, self-advocacy, and “thrivership” in living well with NETs and Neuroendocrine CarcinomaHow collaboration across institutions and disciplines is accelerating progress toward better outcomesThis isn’t just a vision of the future—it’s the work already underway, and the direction the field is moving next. Whether you’re a patient, caregiver, clinician, or advocate, this episode offers clear, accessible insights into the breakthroughs that’s driving the research forward. Please like, share, and subscribe. Your engagement helps us reach more patients and caregivers seeking reliable neuroendocrine cancer information—and supports NETRF’s mission to expand research, awareness, and hope across the NET community. NET specialists included in this episodeUse our episode infographics to get a visual picture of some of the things we have discussed. Po-Hien Ear, PhD Assistant Professor of Surgery (Surgical Oncology & Endocrine Surgery), University of Iowa Carver College of Medicine Martyn Caplin, MD, PhD, FRCP Professor of Gastroenterology & Tumour Neuroendocrinology, Royal Free Hospital & University College London (UCL) Carl Gay, MD, PhD Assistant Professor, Department of Thoracic/Head & Neck Medical Oncology Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Pamela L. Kunz, MD Director, Center for Gastrointestinal Cancers, Smilow Cancer Hospital & Yale Cancer Center Chief, GI Medical Oncology, Yale School of Medicine Neil Renwick, MD, PhD, FRCPC Assistant Professor, Department of Pathology & Molecular Medicine, Queen’s University (SEAMO New Clinician-Scientist Program) Nancy Joseph, MD, PhD Professor of Surgical Pathology, University of California, San Francisco (UCSF) Iacovos Michael, PhD Sunnybrook Research institute and University of Toronto Elsa Hadj Bachir, PhD Research Fellow in Medicine Dana-Farber Cancer Institute Thank you to NETRF staff members Elyse Gellerman and Anna Greene, PhD, and NETRF Board Members Josh Mailman, and Todd Gillman for their contributions to this episode. A special thank you to Jake Dawson and Nancy Lewis for sharing their neuroendocrine cancer journeys. Download a transcript of this episode. The post Episode 51: A New Year— Where We’re Going appeared first on NETRF.

Research has been at the heart of NETRF’s mission for 20 years—and patients are the reason that work matters. Every study we fund is designed to move the field forward and improve how people with neuroendocrine cancer live, feel, and are treated. In this special episode of NETWise, we’re bringing the 2025 NETRF Neuroendocrine Cancer Research Symposium directly to the patient and caregiver community. You’ll hear from leading researchers and clinicians as they explain: What’s changed in neuroendocrine cancer research over the past yearHow new discoveries impact diagnosis, treatment, and everyday patient careWhy NETRF’s 20 years of progress is shaping the future of NETsWhere the field is headed next—scientifically and clinicallyWhether you’re a patient, caregiver, clinician, or advocate, this Year-in-Review episode offers clear, accessible insights into the breakthroughs driving NET research forward. Please like, share, and subscribe. Your engagement helps us reach more patients and caregivers seeking reliable neuroendocrine cancer information—and supports NETRF’s mission to expand research, awareness, and hope across the NET community. NET specialists included in this episodeUse our episode infographics to get a visual picture of some of the things we have discussed. Po-Hien Ear, PhD Assistant Professor of Surgery (Surgical Oncology & Endocrine Surgery), University of Iowa Carver College of Medicine Martyn Caplin, MD, PhD, FRCP Professor of Gastroenterology & Tumour Neuroendocrinology, Royal Free Hospital & University College London (UCL) Carl Gay, MD, PhD Assistant Professor, Department of Thoracic/Head & Neck Medical Oncology Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Pamela L. Kunz, MD Director, Center for Gastrointestinal Cancers, Smilow Cancer Hospital & Yale Cancer Center Chief, GI Medical Oncology, Yale School of Medicine Neil Renwick, MD, PhD, FRCPC Assistant Professor, Department of Pathology & Molecular Medicine, Queen’s University (SEAMO New Clinician-Scientist Program) Nancy Joseph, MD, PhD Professor of Surgical Pathology, University of California, San Francisco (UCSF) Anassuya Ramachandran, PhD Research Fellow at The University of Auckland Thank you to NETRF staff members Elyse Gellerman and Anna Greene, PhD, and NETRF Board Members Josh Mailman, Todd Gillman, and Suzie Ludlow for their contributions to this episode. A special thank you to Jake Dawson, Taylor Dawson and Nancy Lewis for sharing their neuroendocrine cancer journeys. Click here to download a transcript of this episode. The post NETWise Episode 50: The Year in Review 2025: Neuroendocrine Cancer Research and Clinical Progress appeared first on NETRF.

En este episodio de NETWise, continuamos centrándonos en el carcinoma neuroendocrino, una forma rara y agresiva de cáncer neuroendocrino. Si bien en el episodio anterior exploramos el diagnóstico y el tratamiento, este debate se centra en los desafíos únicos que enfrentan los cuidadores. Cuidar a una persona con carcinoma neuroendocrino puede ser increíblemente intenso debido a la rápida progresión del cáncer y las limitadas opciones de tratamiento. Este episodio destaca el impacto emocional y físico del cuidado y enfatiza la importancia vital del autocuidado para quienes apoyan a un ser querido en esta difícil etapa. Reconocimientos profesionales: Jodi Kolada, MA, es Directora de Extensión para Cuidadores y Educación para Miembros del Equipo No Clínico en Well-Spring Solutions en Greensboro, Carolina del Norte. Jodi cuenta con una amplia experiencia en educación y autocuidado para cuidadores. La Dra. Robin Lockridge, Ph.D., es neuropsicóloga en el Instituto Nacional del Cáncer de los Institutos Nacionales de la Salud. Trabaja frecuentemente con cuidadores. Un sincero agradecimiento a Holly Jensen Corte y Shannon Page por compartir sus experiencias con el carcinoma neuroendocrino, y a Jean Carney y Susan Meckler Plummer por compartir sus experiencias de cuidado de carcinoma neuroendocrino. Click here to download a transcript of this episode. The post NETWise Episodio 3: Cuidando al Cuidador del Carcinoma Neuroendocrino appeared first on NETRF.

En este episodio de NETWise, profundizamos en uno de los tipos más agresivos de cáncer neuroendocrino: el carcinoma neuroendocrino. Si bien muchos tumores neuroendocrinos son de crecimiento lento y controlables con el tiempo, el carcinoma neuroendocrino es diferente: se desarrolla rápidamente y requiere atención especializada inmediata. Le guiaremos a través de la información esencial sobre el el carcinoma neuroendocrino, incluyendo: Qué es el carcinoma neuroendocrino y en qué se diferencia de otros tumor neuroendocrinoEl proceso de diagnóstico: qué esperar y cómo los médicos identifican esta enfermedadOpciones de tratamiento actuales y qué deben saber los pacientes y cuidadoresSi usted o un ser querido ha recibido recientemente un diagnóstico de carcinoma neuroendocrino, este episodio está diseñado para ayudarle a comprender el camino a seguir. Click here to download a transcript of this episode. The post NETWise Episodio 2: Carcinoma Neuroendócrino 101 appeared first on NETRF.

In this episode of NETWise, we continue our focus on neuroendocrine carcinoma, a rare and aggressive form of neuroendocrine cancer. While our previous episode explored diagnosis and treatment, this discussion centers on the unique challenges faced by caregivers. Caring for someone with neuroendocrine carcinoma can be incredibly intense due to the cancer’s rapid progression and limited treatment options. This episode highlights the emotional and physical toll of caregiving—and emphasizes the vital importance of self-care for those supporting a loved one through this difficult journey. Resources: https://www.thehealingnet.org/high-grade-neuroendocrinehttps://www.helpforcancercaregivers.orgHigh Grade Neuroendocrine Carcinoma Group Professional acknowledgements: Jodi Kolada, MA, is the Director of Caregiver Outreach and Non-Clinical Team Member Education at Well-Spring Solutions in Greensboro, NC. Jodi has extensive work in caregiver education and caregiver self-care. Dr. Robin Lockridge, Ph.D. is a neuropsychologist at the National Cancer Institute at the National Institutes of Health. She frequently works with caregivers. A sincere thank you to Holly Jensen Corte and Shannon Page for sharing their neuroendocrine carcinoma experiences, and Jean Carney and Susan Meckler Plummer for sharing their neuroendocrine carcinoma caregiving experiences. Click here to download a transcript of this episode. The post NETWise Episode 47: Care for the Neuroendocrine Carcinoma Caregiver appeared first on NETRF.

In this episode of NETWise, we’re diving into one of the more aggressive forms of neuroendocrine cancer: neuroendocrine carcinoma (NEC). While many neuroendocrine tumors are slow-growing and manageable over time, NEC is different—fast-moving and requiring swift, specialized care. We’ll guide you through the essential information about NEC, including: What neuroendocrine carcinoma is and how it differs from other NETsThe diagnostic process: what to expect and how doctors identify this diseaseCurrent treatment options and what patients and caregivers should know If you or a loved one has recently received an NEC diagnosis, this episode is designed to help you start understanding the road ahead. Resources https://www.thehealingnet.org/high-grade-neuroendocrine High Grade Neuroendocrine Carcinoma Group   Acknowledgements Dr. Carl Gay, MD, PhD, is a thoracic medical oncologist and research scientist at the University of Texas MD Anderson Cancer Center. Dr. Aman Chauhan, MD, is a medical oncologist at the Sylvester Comprehensive Cancer Center at the University of Miami, where he leads the neuroendocrine cancer program. Dr. Renuka Iyer is a medical oncologist at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Susan Meckler Plummer, RN, runs an online support group for patients with neuroendocrine carcinoma. Patient Acknowledgements A special thank you to Deb Roberston and Lori Dolnick for sharing their stories. Click here to download a transcript of this episode. The post NETWise Episode 46: Understanding Neuroendocrine Carcinoma appeared first on NETRF.

This episode is part of a collaboration with the FlaNET Carcinoid Community, focusing on financial toxicity. We explore some of the major costs that can arise throughout the neuroendocrine cancer journey and share guidance on how to find helpful resources. NET specialists included in this episodeUse our episode infographics to get a visual picture of some of the things we have discussed. Joanna Doran, JD, is the CEO of Triage Cancer, a national nonprofit that provides free education on legal issues that may impact people diagnosed with cancer. Mysti Motz, BNS, RN, is a nurse who previously worked at the University of Miami’s Sylvester Comprehensive Cancer Center, where she provided care and support to patients in the Neuroendocrine Cancer Program. Samantha Powell, LCSW, is a social worker licensed in Utah and Iowa who has worked with neuroendocrine cancer patients. Sasha Watson, Pharm.D.,is a clinical pharmacist at the University of Miami Sylvester Comprehensive Cancer Center. Thank you to Matt Skinner for sharing his neuroendocrine cancer journey. Additional Resources: Thank you to Triage Cancer for sharing the following resources: Practical Guide to Cancer Rights: https://triagecancer.org/guide Cancer Finances: https://triagecancer.org/cancer-finances Free medical flights: https://www.angelflight.com/ https://angelflightwest.org/angel-flight-services/ https://www.mercymedical.org/free-medical-flights https://skyhope.org/ Cancer and Careers: https://www.cancerandcareers.org/en For veterans diagnosed with cancer: https://www.cancercare.org/publications/340-building_connections_as_a_veteran_resources_and_support American Cancer Society: https://www.cancer.org/cancer/financial-insurance-matters/managing-health-insurance/programs-and-resources-to-help-with-cancer-related-expenses.html Hope Lodge Housing Information: https://www.cancer.org/support-programs-and-services/patient-lodging/hope-lodge.html Nancy’s list: https://nancyslist.org/financial-assistance/ Cancer Care: https://www.cancercare.org/financial_assistance Click here to download a transcript of this episode. The post NETWise Episode 45: Managing the Financial Burden of Neuroendocrine Cancer appeared first on NETRF.

When it comes to PRRT (Peptide Receptor Radionuclide Therapy), patients often have big questions and concerns. In this episode, we dive into the most common questions surrounding PRRT and the broader field of radiopharmaceutical treatments for neuroendocrine cancer. This is an exciting field as there is much more research being done into radiopharmaceuticals for neuroendocrine cancer. Tune in as we break down key insights from doctors and researchers to help you better understand this important treatment option. NET specialists included in this episodeUse our episode infographics to get a visual picture of some of the things we have discussed. Beth Chasen, MD, is a Professor, Department of Nuclear Medicine, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX Victor Fernandes, PHD is a researcher at the University of Wisconsin Madison and a medical physicist by training, I work with radiopharmaceutical therapies and with neuroendocrine tumor patients and patient data. Victor was awarded a research grant by NANETS funded through NETFRF that focuses on Modeling to predict the benefit of PRRT in NET patients. Heather Jacene, MD, is a Clinical Director, Nuclear Medicine/PET-CT Associate Program Director at Brigham and Women’s Joint Program in Nuclear Medicine. In addition, she is an Associate Professor of Radiology Harvard Medical School Click here to download a transcript of this episode. The post NETWise Episode 44: Radiopharmaceutical Treatment – FAQs & Insights appeared first on NETRF.

Artificial intelligence (AI) has become a hot topic, making its way into everyday conversations and industries worldwide. While AI technologies have been around for years, recent advancements are accelerating their impact—especially in healthcare. From improving cancer research to enhancing diagnosis and treatment, AI is reshaping the future of medicine. In this episode of NETWise, we dive into how AI is driving progress in neuroendocrine cancer research and explore its potential applications in the clinic. Could AI revolutionize the way NETs are diagnosed and managed? Join us as we uncover the possibilities. To access the NET Clinical Trial Finder mentioned in this episode: https://netrf.org/for-patients/trial-finder/ NET specialists included in this episodeUse our episode infographics to get a visual picture of some of the things we have discussed. Danielle Ralic is the CEO/CTO and founder of Ancora.ai, a health tech company dedicated to accelerating innovation in medicine by democratizing clinical trial access. Her service uses AI to help neuroendocrine cancer patients find clinical trials. Matthieu Foll, PHD is a researcher at  the International Agency for Research and Cancer, part of the World Health Organization. Emilie Mathian, PHD is a postdoctoral researcher at the International Agency for Research on Cancer (IARC-WHO) Dr.  Aman Chauhan, MD, is a medical oncologist at the University of Miami Sylvester Comprehensive Cancer Center, where he leads the neuroendocrine oncology program and co-directs theranostic drug development. Special Thank you A special thank you to Hector Perez for sharing his neuroendocrine cancer story. Click here to download a transcript of this episode. The post NETWise Episode 43: How Could AI Change Neuroendocrine Cancer? appeared first on NETRF.

Happiness is something that can be difficult to find in life, no matter what. Having an uncommon cancer can make it infinitely harder. In this episode of NETWise, we’re going to talk about what happiness means, and how cancer can affect the way we think about it. We’ll also talk about the things we all can do to be more resilient. NET specialists included in this episodeUse our episode infographics to get a visual picture of some of the things we have discussed. James A. Bibb, PhD is a researcher at the University of Arizona College of Health Sciences.   Dr. Bibb’s research focuses on basic and translational research exploring the molecular mechanisms of intracellular signal transduction in health and disease. His work on the regulation of dopamine neurotransmission was cited in the Nobel Prize in Physiology for Medicine in 2000.  Robin Lockridge, Ph.D. is a neuropsychologist at the National Cancer Institute at the National Institutes of Health with expertise in the clinical assessment of pediatric cognitive, neurodevelopmental, and neuropsychological disorders as well as children and youth program development. Dr. Lockridge works with the Adult Rare Tumor Network.   Kevin Payne, Ph.D. is a social psychologist and is the founder of an organization,  Your Life Lived Well, LLC.,  dedicated to helping people thrive with the challenges of chronic illness. Lori Wiener, Ph.D., DCSW, LCSW-C is a clinical social worker. She directs the psychosocial support and research program at the National Cancer Institute. Thank you to Burt Rosen and Nancy Lewis for sharing their neuroendocrine cancer stories and personal perspectives. Click here to download a transcript of this episode. The post NETWise Episode 42: Finding Happiness While Living with Neuroendocrine Cancer appeared first on NETRF.